The NLRP3 inflammasome is a well-studied target for the treatment of multiple inflammatory diseases, but how to promote the current therapeutics remains a large challenge. CRISPR/ Cas9, as a gene editing tool, allows for direct ablation of NLRP3 at the genomic level. In this study, we screen an optimized cationic lipid-assisted nanoparticle (CLAN) to deliver Cas9 mRNA (mCas9) and guide RNA (gRNA) into macrophages. By using CLAN encapsulating mCas9 and gRNA-targeting NLRP3 (gNLRP3) (CLAN mCas9/gNLRP3 ), we disrupt NLRP3 of macrophages, inhibiting the activation of the NLRP3 inflammasome in response to diverse stimuli. After intravenous injection, CLAN mCas9/gNLRP3 mitigates acute inflammation of LPSinduced septic shock and monosodium urate crystal (MSU)-induced peritonitis. In addition, CLAN mCas9/gNLRP3 treatment improves insulin sensitivity and reduces adipose inflammation of high-fat-diet (HFD)-induced type 2 diabetes (T2D). Thus, our study provides a promising strategy for treating NLRP3-dependent inflammatory diseases and provides a carrier for delivering CRISPR/Cas9 into macrophages.
T he NLR family protein NLRP3 is a cytosolic sensor of exogenous pathogens and endogenous damage-associated molecular patterns (DAMPs) 1, 2 . Upon activation, NLRP3 assembles with the adapter protein ASC and cysteine protease caspase-1 to form the NLRP3 inflammasome, resulting in the cleavage and activation of caspase-1. Activated capase-1 cleaves the precursors of IL-1β and IL-18 into mature forms and cause the release of several proinflammatory cytokines, including IL-1β and IL-18 3, 4 . It was reported that the NLRP3 inflammasome plays critical roles in the initiation and progression of diverse inflammatory diseases [5] [6] [7] . Inhibition of the NLRP3 inflammasome signal has been shown to be effective in attenuating septic shock 8, 9 , peritonitis 8,10,11 , Alzheimer's disease 12 , atherosclerosis 13 , T2D [14] [15] [16] , multiple sclerosis 17, 18 , and gout 19 , among other diseases. Thus, the NLRP3 inflammasome is an excellent target for the treatment of multiple inflammatory diseases.
Current strategies targeting the NLRP3 inflammasome mainly includes anti-inflammatory biologics targeting IL-1 signal (such as IL-1 receptor antagonist Kineret, neutralizing IL-1β antibody ILARIS and soluble decoy IL-1 receptor Arcalyst) [20] [21] [22] , smallmolecule inhibitors (such as glyburide and MCC950) and natural inhibitors of the NLRP3 inflammasome (such as omega-3 fatty acids, dopamine, and β-hydroxybutyrate) 8, 11, 16, 18, 23 . Biologics targeting the IL-1 signal only block the partial downstream signal of the NLRP3 inflammasome, and the compensation effect between different inflammatory mediators limits their therapeutic efficiency 20, 24, 25 . Except for the recently reported inhibitor CY-09 by Zhou et al. 26 most well-studied inhibitors usually inhibit the upstream signal of the NLRP3 inflammasome, not NLRP3 itself 26 , which limits their efficiency and may causes unexpected side effects. CRISPR/Cas9, as a third-generation genome editing tool, can specifically and effectively disrupt or repair disease-causing genes by a single gRNA-directed Cas9 nuclease 16, [27] [28] [29] . Using CRISPR/Cas9 to directly disrupt the key molecule-NLRP3 at the genomic level can not only completely inhibit the activation of NLRP3 inflammasome, but also avoid the potential risks of inhibiting off-target pathways of anti-inflammatory biologics and inhibitors. Development of a strategy to knock out NLRP3 with CRISPR/Cas9 is expected to be a more effective therapy for diverse inflammatory diseases 30 .
Thus far, CRISPR/Cas9-modified T-cells in vitro have entered a clinical trial for the treatment of metastatic non-small cell lung cancer 31 . Adenovirus-associated or adeno-associated virus (AAV)-mediated delivery of CRISPR/Cas9 has been used to treat diseases such as hypercholesterolemia and Duchenne muscular dystrophy [32] [33] [34] [35] . Non-viral delivery systems have also been developed to deliver the CRSPR/Cas9 plasmid, mRNA/gRNA or the Cas9/gRNA ribonucleoprotein complex for in vivo genome editing [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] . For example, Anderson et al. successfully treated FAH gene mutation induced-hereditary tyrosinemia using lipid nanoparticles and AAV-delivered mCas9/gRNA 37 . Wei et al. constructed a "core-shell" artificial virus (RRPHC) to deliver CRISPR/Cas9 plasmid for MTH1 gene disruption, significantly inhibiting SKOV3 xenograft tumor growth 36 . Thus, direct knockout of NLRP3 by CRISPR/Cas9-mediated gene editing is feasible for inflammatory disease treatment.
In this study, we report a systemic delivery system of CRISPR/ Cas9 by encapsulating mCas9 and gNLRP3 into CLAN. CLAN is a type of PEG-b-PLGA-based nanoparticle assisted by cationic lipid BHEM-Chol for nucleic acid therapeutics delivery. In our previous work, we have delivered small interfering RNA, RNA aptamers and hepatitis B virus CpG into tumor cells, cardiomyocytes, macrophages or plasmacytoid dendritic cells with CLAN 10, [49] [50] [51] . However, mCas9/gNLRP3 are different from other nucleic acid therapeutics, and the properties of nanoparticles impact the efficiency of drug delivery. Therefore, we create a library of CLANs of different surface charge and PEG density by adjusting the weight of the cationic lipid BHEM-Chol and mass fraction of PEG 5K -b-PLGA 11K in polymers. We screen CLANs both in vitro and in vivo and select a preferable CLAN to deliver mCas9/gNLRP3 into macrophages, which ameliorates LPSinduced septic shock, MSU-induced peritonitis and HFDinduced T2D by disrupting NLRP3 in macrophages. Our study provides a promising strategy for the delivery of CRISPR/Cas9 into macrophages and treatment of multiple inflammatory diseases.
Results
Screening of a preferable CLAN for mCas9/gRNA delivery. It was reported that the in vivo fates of diverse nanoparticles, including polymeric nanoparticles, are closely related to their nano-properties 52, 53 . Rational design of the surface charge and PEG density of polymeric nanoparticles can enhance their internalization of target cells, including macrophages [53] [54] [55] . To fabricate a CLAN that is suitable for delivering mCas9/gRNA into macrophages, we designed a screening process (Fig. 1a ).
First, we created a library containing 16 CLANs (CLAN11 to CLAN44) of different surface charge and PEG density. The components for CLAN preparation are shown in Supplementary  Table 1 . Briefly, the surface charge of CLAN was regulated by adjusting the weight of BHEM-Chol and the surface PEG density of CLAN was regulated by adjusting the mass fraction of PEG 5Kb-PLGA 11K in polymers. Next, we characterized the properties of CLANs. The surface charge of CLANs ranged from 5.0 to 31.1 mV and was increased with the increase in BHEM-Chol ( Supplementary Fig. 1a ). To verify the PEG density of CLANs, we used 1 H NMR to detect the mass fraction of PEG 5K -b-PLGA 11K , which is PEGylated, and used it to represent the relative PEG density of each CLAN. As shown in Supplementary  Fig. 1b , the mass fraction of PEG 5K -b-PLGA 11K in polymers was decreased along with the increase in PLGA 11K . The diameter of each CLAN was similar (approximately 130 nm, Supplementary  Fig. 1c ). To facilitate the screening of CLANs with better macrophage uptake in vivo, we encapsulated Cy5-labeled siRNA (Cy5-siRNA) into CLANs to label them, and denoted them as CLAN Cy5-siRNA . The encapsulation efficacy of Cy5-siRNA in CLANs was measured by high-performance liquid chromatography (HPLC) and was higher than 90% ( Supplementary  Fig. 1d ).
Subsequently, we detected the macrophage uptake of CLAN Cy5-siRNA . Macrophages of mice intravenously injected with CLAN Cy5-siRNA were isolated and subjected to fluorescenceactivated cell sorting (FACS) analysis. The relative uptake quantity of CLAN Cy5-siRNA was calculated as described in the Methods section. As shown in Fig. 1b and Supplementary Fig. 2 , CLAN42 showed the highest relative uptake quantity of macrophages from the peritoneal cavity, liver, peripheral blood, spleen and adipose tissue. This result was consistent with other reports that increasing the surface charge of nanoparticles can increase cellular uptake 53, 54 , but the surface PEG density of CLANs was not always the lower the better.
Next, we selected CLAN42 for mCas9/gRNA delivery. Four other CLANs (CLAN11, CLAN14, CLAN41, and CLAN44) of distinct surface charge and PEG density were selected as controls. The properties of CLANs encapsulating mCas9/gRNA were characterized ( Supplementary Fig. 3 ). The surface charges of CLAN42 and two other CLANs (CLAN41 and CLAN44) were similar (31.5 mV ± 5.84 mV, 30.7 mV ± 5.61 mV, and 31.4 mV ± 6.14 mV, respectively), and higher than those of CLAN11 and CLAN14 (9.62 mV ± 4.11 mV and 10.8 mV ± 4.37 mV, respectively) ( Supplementary Fig. 3a ). Additionally, five CLANs had a similar diameter, morphology, and colloidal stability (Supplementary Fig. 3b-d ). Five CLANs all could effectively encapsulate mCas9/gRNA, and the encapsulation efficiency was higher than 90% (Supplementary Table 2 ). We also tested whether CLANs could protect mCas9/gRNA in the physiological environment by incubating CLAN mCas9/gRNA with 20 μg ml −1 RNase A. As demonstrated in Supplementary Fig. 4 , mCas9 and gRNA both maintained their integrity with the encapsulation of five CLANs.
To test whether CLAN42 could effectively deliver mCas9/ gRNA, we encapsulated Cas9 and enhanced green fluorescent protein (EGFP) co-expressing mRNA (Cas9-EGFP mRNA, or mCas9-EGFP) and negative control gRNA (gNC) into selected CLANs (CLAN mCas9-EGFP/gNC ). Bone marrow-derived macrophages (BMDMs) were transfected with different CLAN mCas9-EGFP/gNC . As displayed in Fig. 1c (65.8%). Next, we detected the gene knockout efficiency by transfecting Raw264.7 cells (a macrophage cell line) stably expressing GFP (Raw264.7-GFP) with CLANs encapsulating mCas9 and gRNA-targeting GFP (gGFP) (CLAN mCas9/gGFP ). The percentage of GFP-knockout (KO) Raw264.7-GFP cells in the CLAN42 transfection group was the highest and reached 53.9% ( Fig. 1d ). We further confirmed the in vivo mCas9/gRNA delivery efficiency of CLAN42 by injecting mice with different CLAN mCas9-EGFP/gNC . Similar to Fig. 1c , the percentage of EGFPpositive peritoneal macrophages in the CLAN42 injection group was the highest (48.4%) ( Fig. 1e ). Taken together, CLAN42 was the most effective CLAN in mCas9/gRNA delivery due to its highest ability of macrophage uptake, and CLAN42 was preferred to encapsulate mCas9/gNLRP3 (denoted as CLAN mCas9/gNLRP3 ) for multiple inflammatory disease treatments.
Localization and integrity of CLAN42 after internalization. Before applying CLAN mCas9/gNLRP3 for inflammatory disease treatments, we firstly studied its intracellular localization. We encapsulated Cy5-labeled mCas9 and gRNA into the screened CLAN42, denoted as CLAN Cy5-mCas9/gRNA . Subsequently, BMDMs were transfected with CLAN Cy5-mCas9/gRNA . As displayed in Supplementary Fig. 5 , most of CLAN Cy5-mCas9/gRNA colocalized with EEA1-positive endosome at 0 h after transfection. This result indicated that CLAN Cy5-mCas9/gRNA was internalized by macrophages by the endocytosis pathway and accumulated in the endosome after uptake. With the elongation of incubating time from 0 to 24 h, the red fluorescence of Cy5 gradually separated with the green fluorescence of the endosome, indicating that CLAN Cy5-mCas9/gRNA escaped from the endosome into the cytoplasm. In addition, the number of the endosome at 24 h was significantly lower than that at 12 or 6 h. We speculated that the escape of CLAN Cy5-mCas9/gRNA from the endosome was due to the disruption of the endosome. Besides, Cy5 signal was not observed in the nucleus (DAPI positive), indicating that neither CLAN Cy5-mCas9/gRNA nor Cy5-mCas9 passed into the nucleus. The fluorescence of Cas9 protein was observed in the cytoplasm and the nucleus at 6 h after transfection and Cas9 protein in the nucleus was increased at 12 and 24 h, suggesting that Cas9 was translated from mRNA into protein in the cytoplasm, and subsequently entered the nucleus under the guide of nuclear localization signal (NLS) co-expressed with Cas9. Subsequently, we analyzed the integrity of CLAN42 after internalization by macrophages with a Förster Resonance Energy Transfer (FRET) experiment, and selected FITC (maximal excitation:~490 nm, maximal emission:~525 nm) and Rhodamine (maximal excitation:~550 nm, maximal emission:~590 nm) as the donor and acceptor molecules of FRET couple, respectively. FITC-conjugated PLGA 11K and Rhodamineconjugated PLGA 11K were used to fabricated CLAN42, denoted as CLAN FRET . CLAN fabricated with only FITC-conjugated PLGA 11K was denoted as CLAN FITC and CLAN fabricated with only Rhodamine-conjugated PLGA 11K was denoted as CLAN Rho . As shown in Supplementary Fig. 6a , at 521 nm, the fluorescence intensity of CLAN FRET was 6384, which was significantly lower than that of CLAN FITC (17713). At 592 nm, the fluorescence intensity of CLAN FRET was 18352, which was significantly higher than that of CLAN Rho (3250). These results indicated that the energy of FITC was transferred to Rhodamine when CLAN FRET was intact. Then, we transfected BMDMs with CLAN FRET . As shown in Supplementary Fig. 6b , at 0 h after transfection, the fluorescence signal of Rhodamine was very strong while that of FITC was very weak, indicating that the energy of FITC was transferred to Rhodamine and CLAN42 was intact at this time. With the elongation of incubating time, the fluorescence signal of Rhodamine decreased while that of FITC increased, indicating that the distance between Rhodamine and FITC increased and CLAN42 was broken or degraded. From these results, we can conclude that CLAN42 was gradually broken or degraded within 24 h after internalization by macrophages.
In addition, we detected the cytotoxicity of our CLAN42 by MTT assay. As shown in Supplementary Fig. 7 , the cell viability of BMDMs incubated with CLAN42 (96.1%) and CLAN mCas9/gRNA (97.3%) was similar to that of PBS control, indicating that our CLAN42 was not cytotoxic. CLAN mCas9/gNLRP3 disrupts NLRP3 of macrophages in vitro. Before detecting the knockout efficiency of CLAN mCas9/gNLRP3 , we first analyzed Cas9 expression after CLAN mCas9/gNLRP3 transfection. As demonstrated in Fig. 2a , Cas9 was efficiently expressed in BMDMs 12 and 24 h after CLAN mCas9/gNLRP3 transfection, and the amount of protein expressed was correlated with the dose of Cas9 mRNA and time after transfection. Additionally, mCas9/ gNLRP3 transfected by Lipofectamine MessengerMAX (Lipo m-Cas9/gNLRP3) and pX330/gNLRP3 plasmid transfected with Lipofectamine 3000 (LipopCas9/gNLRP3 ) also showed Cas9 expression, and Cas9 expression of Lipo mCas9/gNLRP3 was higher than that in Lipo pCas9/gNLRP3 within 24 h. By contrast, BMDMs transfected with phosphatebuffered saline (PBS) or free mCas9/gNLRP3 (Free mCas9/gNLRP3 ) showed no Cas9 expression. Next, we detected the knockout efficiency by the T7 endonuclease I (T7E1) assay. The insertion/ deletion (indel) frequency in the NLRP3 locus of BMDMs transfected with CLAN mCas9/gNLRP3 at the dose of 0.85 nM was 16.3% at 12 h and increased to 35.6% at 24 h (Fig. 2b) . The indel frequency of CLAN mCas9/gNLRP3 was also dose-dependent and reached 70.2% at 24 h for the dose of 2.6 nM. The representative sequences of indels in the NLRP3 locus of BMDMs transfected with CLAN mCas9/gNLRP3 are shown in Fig. 2c and Supplementary  Fig. 8 . Furthermore, the knockout efficiency was confirmed by detecting the protein expression of NLRP3. As shown in Fig. 2d , NLRP3 expression was reduced with CLAN mCas9/gNLRP3 transfection, and the reduction was also dose dependent. Meanwhile, the expression of three other inflammasome proteins, NLRP1, NLRC4 and AIM2, were not affected by the knockout of NLRP3. CLAN mCas9/gNLRP3 inhibits NLRP3 inflammasome activation. We next tested whether CLAN mCas9/gNLRP3 -mediated NLRP3 knockout could inhibit the activation of the NLRP3 inflammasome. We transfected BMDMs with CLAN mCas9/gNLRP3 , and then stimulated BMDMs with the NLRP3 inflammasome stimulus nigericin after LPS priming 8 . As shown in Fig. 3a , compared with the Free mCas9/gNLRP3 or CLAN mCas9/gNC group, CLAN mCas9/gNLRP3 transfection dose-dependently inhibited the release of IL-1β into the supernatants (Sup.) of BMDMs. The amount of caspase-1 p10 (Casp-1 p10, an auto-cleaved fragment of caspase-1) was also dose-dependently reduced in the supernatants. The knockout efficiency of NLRP3 was confirmed by detecting NLRP3 protein expression in the cell lysates (Lys.) of BMDMs'. These results suggested that CLAN mCas9/gNLRP3 inhibited NLRP3 inflammasome activation via disrupting NLRP3. Moreover, the inhibition efficiency of CLAN mCas9/gNLRP3 at a dose of 2.6 nM was similar to that of glyburide (NLRP3 inflammasome inhibitor) 23 . Expression of IL-1β precursor (pro-IL-1β) and caspase-1 precursor (Casp-1 p45) was not affected by CLAN mCas9/gNLRP3 .
Because ASC oligomerization is a key event in NLRP3 inflammasome activation 3,4,18 , we detected the formation of ASC oligomers in cross-linked cytosolic pellets of BMDMs. As displayed in Fig. 3b , ASC monomers (22 kDa) and higher order oligomers in cross-linked cytosolic pellets were attenuated by CLAN mCas9/gNLRP3 transfection or glyburide treatment. The difference was that CLAN mCas9/gNLRP3 inhibited ASC oligomerization by reducing NLRP3 expression while glyburide suppressed NLRP3-ASC interaction 23 . In addition, the expression of ASC monomers in the cell lysates was correspondingly increased with the inhibition of ASC oligomerization after CLAN mCas9/gNLRP3 transfection or glyburide treatment ( Supplementary Fig. 9 ). Furthermore, we measured the release of IL-1β and IL-18 (another released cytokine of NLRP3 inflammasome activation) with ELISA. The release of IL-1β and IL-18 were dosedependently reduced by CLAN mCas9/gNLRP3 transfection ( Fig. 3c-d ), but TNF-α secretion, which was not dependent on the NLRP3 inflammasome 56 , was not significantly affected by CLAN mCas9/gNLRP3 and glyburide ( Fig. 3e ).
Subsequently, we tested whether NLRP3 inflammasome activation induced by other stimuli could be inhibited by CLAN mCas9/gNLRP3 -mediated NLRP3 knockout. The results showed that IL-1β secretion and caspase-1 cleavage induced by diverse stimuli (including MSU, nigericin, ATP and silica) were all inhibited by CLAN mCas9/gNLRP3 -mediated NLRP3 knockout ( Fig. 3f , g) 8 . These results suggested that CLAN mCas9/gNLRP3mediated NLRP3 knockout is a potent strategy for the treatment of inflammatory diseases caused by diverse stimuli.
CLAN mCas9/gNLRP3 mediates NLRP3 knockout in vivo. Before applying CLAN mCas9/gNLRP3 to treat NLRP3-associated inflammatory diseases, we detected its NLRP3 knockout efficiency in vivo. C57BL/6 mice were injected with CLAN mCas9/gNLRP3 at the dose of 0.5, 1, or 2 mg total RNA per kg body weight (0.5, 1, or 2 mg kg −1 ). Mice injected with PBS, Free mCas9/gNLRP3 (2 mg kg −1 ) or CLAN mCas9/gNC (2 mg kg −1 ) were used as control. Similar to the in vitro results, Cas9 protein was dose-dependently expressed in peritoneal macrophages at 12 or 24 h after CLAN mCas9/gNLRP3 injection ( Fig. 4a ). Next, we measured the NLRP3 knockout efficiency of CLAN mCas9/gNLRP3 by detecting indels in the targeting locus of peritoneal macrophages using the T7E1 assay. The data showed that the indel frequency was dose-dependent and timedependent, and reached 47.1% at 24 h after CLAN mCas9/gNLRP3 (2 mg kg −1 ) injection (Fig. 4b ). The representative sequences of indels in the NLRP3 locus of peritoneal macrophages from mice injected with CLAN mCas9/gNLRP3 (2 mg kg −1 ) are displayed in Fig. 4c and Supplementary Fig. 10 . Expression of the NLRP3 protein in peritoneal macrophages was also analyzed and showed that NLRP3 expression was dose-dependently inhibited by CLAN mCas9/gNLRP3 , while other inflammasome proteins, including NLRP1, NLRC4 and AIM2, were not affected (Fig. 4d ). The expression of NLRP3 in CLAN mCas9/gNLRP3 groups at the doses of 0.5, 1, and 2 mg kg −1 was 81.5, 64.3, and 56.8% of that in PBS group, respectively ( Fig. 4d ). Considering that mice were only injected with CLAN mCas9/gNLRP3 for a single injection, the knockout efficiency was acceptable. Because off-target effects are a large concern for the clinical application of CRISPR/Cas9 57 , we isolated the genome of peritoneal macrophages at 72 h after CLAN mCas9/gNLRP3 (2 mg kg −1 ) injection and detected the indel frequency in potential off-target sites of NLRP3 gRNA. As shown in Supplementary Fig. 11 , the indel frequency in six potential offtarget sites was lower than 0.5%, while the indel frequency in the NLRP3 locus was 58.6%. These results indicated that CLAN mCas9/ gNLRP3 could disrupt the NLRP3 gene of macrophages in vivo with a low off-target effect.
CLAN mCas9/gNLRP3 mitigates LPS-induced septic shock. We have demonstrated that CLAN mCas9/gNLRP3 can inhibit NLRP3 inflammasome activation via disrupting NLRP3 of macrophages. We next investigated whether CLAN mCas9/gNLRP3 could be used to treat inflammatory diseases. It was reported that LPS-induced septic shock is NLRP3 inflammasome dependent, and the inhibition of its activation could mitigate septic shock 8, 9 . Thus, we pre-treated mice with CLAN mCas9/gNLRP3 and then challenged the mice with LPS to induce septic shock ( Fig. 5a ). As shown in Fig. 5a The results showed that CLAN mCas9/gNLRP3 dosedependently inhibited the production of serum IL-1β and caspase-1 p10, which was in accordance with the reduction of NLRP3 expression in peritoneal macrophages (Fig. 5b ). ELISA revealed that the production of IL-1β and IL-18 in the serum were inhibited by CLAN mCas9/gNLRP3 (Fig. 5c, d ). In addition, CLAN mCas9/gNLRP3 had only a mild effect on the production of serum TNF-α (Fig. 5e ). These results suggested that CLAN mCas9/ gNLRP3 could inhibit NLRP3 inflammasome activation in vivo via NLRP3 knockout and could mitigate LPS-induced septic shock.
In addition, we compared the efficacy of our CLAN mCas9/ gNLRP3 with the specific inhibitor of NLRP3 inflammasome (MCC950) 18 . As shown in Supplementary Fig. 12a , compared with PBS group, both CLAN mCas9/gNLRP3 and MCC950 treatments extended the survival of LPS-challenged mice. The survival of mice treated with CLAN mCas9/gNLRP3 was longer than that of mice treated with MCC950 (log-rank test: P = 0.028). The median survival duration for the CLAN mCas9/gNLRP3 -treated group was 44 h while that of the MCC950-treated group was 38 h. The secretion of IL-1β was inhibited by the treatments of CLAN mCas9/gNLRP3 and MCC950, and CLAN mCas9/gNLRP3 was more effective than MCC950 ( Supplementary Fig. 12b ). The reason was that the half-life of MCC950 is very short while CLAN mCas9/gNLRP3 -mediated NLRP3 knockout can last for a longer period of time as long as the edited macrophages are still alive 18 .
CLAN mCas9/gNLRP3 mitigates MSU-induced peritonitis. Because we have demonstrated that CLAN mCas9/gNLRP3 was capable of mitigating LPS-induced systemic inflammation, we further studied the protective effect of CLAN mCas9/gNLRP3 on periphery inflammation. Similarly, we pre-treated mice with CLAN mCas9/ gNLRP3 and then challenged the mice with MSU to induce peritonitis ( Fig. 6a ), which is also NLRP3 inflammasome dependent 8, 10 . Peritoneal lavage fluid of the mice was collected 6 h after MSU injection. As shown in Fig. 6a , intraperitoneal administration of MSU increased the percentage of neutrophils (CD11b + Ly6G + ) in the peritoneal cavity (from 4.48% to more than 80%), and CLAN mCas9/gNLRP3 treatment could dosedependently reduce the recruitment of neutrophils. Correspondingly, the total number of neutrophils accumulated in the peritoneal cavity was also reduced by CLAN mCas9/gNLRP3 (Fig. 6b ). Moreover, we detected the production of IL-1β in the peritoneal lavage fluid and NLRP3 expression in peritoneal macrophages. The results showed that CLAN mCas9/gNLRP3 treatment inhibited MSU-induced IL-1β production in a dose-dependent manner (Fig. 6c ) in accordance with the knockout efficiency of NLRP3 (Fig. 6d ). From these results, we can conclude that CLAN mCas9/ gNLRP3 -mediated NLRP3 knockout in vivo can be used to attenuate systemic and peritoneal inflammation by inhibiting NLRP3 inflammasome activation.
Amelioration of HFD-induced T2D with CLAN mCas9/gNLRP3 . The T2D incidence has greatly increased in recent years and has ARTICLE become a large threat to health worldwide. Previous studies have shown that inflammation is a key contributor to insulin resistance and T2D, and the NLRP3 inflammasome plays a critical role in the development of insulin resistance in T2D [14] [15] [16] . We thus investigated whether CLAN mCas9/gNLRP3 can treat T2D by intravenously injecting HFD-induced T2D mice with CLAN mCas9/ gNLRP3 (Fig. 7a ). As shown in Fig. 7b , the plasma glucose in the fasted states was dose-dependently reduced by CLAN mCas9/gNLRP3 treatment, indicating that CLAN mCas9/gNLRP3 ameliorated HFDinduced insulin resistance. To confirm the treatment effects of CLAN mCas9/gNLRP3 , we performed the glucose tolerance test (GTT) and insulin tolerance test (ITT) in HFD-induced T2D mice with different treatments. As shown in Fig. 7c , the glucose tolerance of T2D mice treated with CLAN mCas9/gNLRP3 was superior to that of T2D mice treated with PBS, Free mCas9/gNLRP3 or CLAN mCas9/gNC . CLAN mCas9/gNLRP3 (2 mg kg −1 ) treatment showed similar improvement with the glyburide (a commercialized NLRP3 inflammasome inhibitor for T2D therapy) group 23 . Additionally, ITT also showed consistent results such that insulin sensitivity was enhanced after CLAN mCas9/gNLRP3 treatment (Fig. 7d ). The reduction in plasma glucose after insulin administration in the CLAN mCas9/gNLRP3 group was similar to that in the glyburide group (Fig. 7d ). The improvement of CLAN mCas9/ gNLRP3 treatment on glucose tolerance and insulin sensitivity also displayed a dose-dependent effect ( Supplementary Fig. 13 ).
To further confirm that CLAN mCas9/gNLRP3 improved the symptoms of HFD-induced T2D through NLRP3 knockoutmediated inhibition of the NLRP3 inflammasome, we detected the expression of IL-1β, cleaved caspase-1 p10 and NLRP3 in white adipose tissue (WAT) of mice with different treatments. Compared with T2D mice treated with PBS, Free mCas9/gNLRP3 or CLAN mCas9/gNC , IL-1β secretion and caspase-1 cleavage in WAT was dose-dependently reduced by CLAM mCas9/gNLRP3 treatment (Fig. 7e ). In addition, the inhibition of NLRP3 inflammasome activation was consistent with the NLRP3 knockout efficiency of CLAN mCas9/gNLRP3 treatments (Fig. 7e) . The secretion of IL-1β and IL-18 in WAT as measured by ELISA also indicated dose-dependent inhibition of the NLRP3 inflammasome with CLAN mCas9/gNLRP3 treatments (Fig. 7f, g) . As shown in Fig. 7e -g, the secretion of IL-1β and IL-18 was also inhibited in glyburide-treated T2D mice, indicating that the activation of NLRP3 inflammasome was inhibited by glyburide in vivo, although glyburide didn't directly inhibit NLRP3 protein 23 . As to the improvement of T2D symptoms achieved by glyburide, it was not only due to its inhibition on NLRP3 inflammasome, but also may because of the effects of cyclohexylurea group on insulin secretion 23 . Furthermore, the secretion of two other proinflammatory cytokines, TNF-α and MCP-1, was dose-dependently inhibited by CLAN mCas9/gNLRP3 treatments, suggesting that CLAN mCas9/gNLRP3 -mediated NLRP3 knockout could improve the overall inflammatory environment in WAT (Fig. 7h, i) . In summary, CLAN mCas9/ gNLRP3 -mediated NLRP3 knockout can improve the glucose tolerance and insulin sensitivity of HFD-induced T2D and ameliorate the inflammation of adipose tissue through inhibition of NLRP3 inflammasome activation. 
Discussion
In this study, we selected the NLRP3 inflammasome as the therapeutic target, which is a major mediator of acute/chronic inflammation and has been proven to be an effective target for the treatment of multiple inflammatory diseases [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . Nevertheless, current therapeutics targeting NLRP3 inflammasome, including inhibitors of upstream signals of the NLRP3 inflammasome or biologics targeting IL-1β or its receptors, either indirectly inhibit NLRP3 or only partially inhibit the signal of the NLRP3 inflammasome, limiting their therapeutic efficiency 20, [24] [25] [26] . The CRISPR/Cas9 genome editing tool, which is of high efficiency, high specificity and simplicity 29 , provides a good strategy for directly targeting NLRP3 and completely ablating NLRP3dependent inflammation. The only barrier for applying CRISPR/Cas9 to the treatment of inflammatory diseases is how to efficiently deliver Cas9 and gRNA into immune cells, especially macrophages 58 . Several non-viral delivery systems have been used to deliver the Cas9/gRNA ribonucleoprotein complex, mRNA/ gRNA or plasmids into hepatocytes, tumor cells or some tissue cells in vivo; no delivery system targeting macrophages have been reported 59, 60 .
Our study has screened the polymer nanoparticle CLAN with optimized properties for delivering Cas9 mRNA and gRNA into macrophages for gene editing. The results showed that, within a certain range, CLAN with a higher surface charge and lower PEG density could be internalized by macrophages more efficiently 54, 55 . Increasing the surface charge was more effective than reducing the PEG density. Because mRNA and gNLRP3 can be rapidly degraded after gene editing, genomic ablation of NLRP3 would not cause integration mutations of the genome. We have demonstrated that screened CLAN could encapsulate mCas9/gNLRP3 and protect mCas9/gNLRP3 from RNase of the physiological environment. We next demonstrated that CLAN mCas9/gNLRP3 transfection could express Cas9 protein within several hours and disrupt the NLRP3 gene in BMDMs, inhibiting the activation of the NLRP3 inflammasome in response to diverse stimuli. The secretion of both proinflammatory cytokines IL-1β and IL-18 was reduced by CLAN mCas9/gNLRP3 . We noted that CLAN mCas9/gNLRP3 did not completely inactivate the NLRP3 inflammasome; thus, it is possible that the transfection efficiency was not 100%. Future work will aim to enhance other properties of CLAN to increase its transfection efficiency.
Furthermore, we have demonstrated that CLAN mCas9/gNLRP3 was capable of dose-dependently disrupting NLRP3 of macrophages in vivo. Because off-target effects are a huge concern for the clinical application of CRISPR/Cas9 57 , we detected the indel frequency in the predicted off-target sites after the intravenous injection of CLAN mCas9/gNLRP3 . Our results showed that only a low off-target effect was detected in macrophages. In addition, our CLAN was internalized by different immunocytes, including macrophages, neutrophils, T and B cells, but only macrophages and neutrophils, which have strong phagocytic activity, can effectively internalize it ( Supplementary Fig. 14) . Because NLRP3 only functions in macrophages, disruption of NLRP3 gene in other cells won't cause foreseeable side effects. And the life-span of macrophages ranges from 6 to 16 days, the disrupted NLRP3 of macrophages will recover in a short time and won't cause permanent NLRP3 inhibition. Thus, CLAN mCas9/gNLRP3 has great potential for the clinical treatment of NLRP3-dependent inflammatory diseases. We have applied CLAN mCas9/gNLRP3 for the prevention of LPS-induced septic shock and MSU-induced peritonitis, and it mitigated the acute inflammatory responses. CLAN mCas9/gNLRP3 was unable to entirely prevent septic shock and peritonitis likely because of the activation of other inflammasomes, such as NLRP1, NLRC4, and AIM2 3, 5, 7 , and the inactivation of the NLRP3 inflammasome was insufficient to inhibit acute inflammation. In the treatment of HFD-induced T2D, CLAN mCas9/gNLRP3 reduced chronic inflammation in adipose tissue and improved insulin sensitivity via the knockout of NLRP3. Additionally, the dosing frequency of CLAN mCas9/gNLRP3 was lower than that of commercialized glyburide, which is injected daily. Thus, CLAN mCas9/gNLRP3 was an effective therapeutic for T2D, and its therapeutic effect was likely to last longer due to the genomic ablation of NLRP3.
In conclusion, we have developed a strategy to deliver Cas9 mRNA and gRNA into macrophages for gene editing. Delivery of mCas9/gNLRP3 with CLAN could mitigate acute and chronic inflammatory diseases. Our results have proven CLAN mCas9/ gNLRP3 to be a promising therapy for NLRP3-dependent inflammatory diseases. Our study also provided an example for treating immune-related diseases by nanoparticles-mediated gene editing of immune cells.
Methods
Materials and reagents. N,N-Bis(2-hydroxyethyl)-N-methyl-N-(2-cholesteryoxycarbonyl-aminoethyl) ammonium bromide (BHEM-Chol), PEG 5K -b-PLGA 11K (molar ratio: LA/GA = 75/25) and PLGA 11K (molar ratio: LA/GA = 75/25) polymers were synthesized, purified and characterized as previously reported 61, 62 . Cy5-siRNA containing a scrambled sequence (antisense strand, 5′-ACGUGACACGU UCGGAGAAdTdT-3′) was provided by Suzhou Ribo Life Science Co. Ltd. (Kunshan, China). mCas9 or mCas9-EGFP gRNAs were prepared by in vitro transcription (IVT) according to the manufacturer's instructions. mCas9 or mCas9-EGFP was prepared using the HiScribe™ T7 ARCA mRNA Kit (with tailing) (New England Biolabs, MA, USA) and PCR amplification products of pX330 or pX458 (addgene) as a template. gRNAs (gNLRP3, gGFP and gNC) were designed using the CRISPR.mit.edu platform, cloned into pX330 or pX458 (oligos were listed in Supplementary Table 3 ) 63 and then prepared using the HiScribe™ T7 Quick High Yield RNA Synthesis Kit (New England Biolabs, MA, USA). Primers for IVT of mRNA and gRNAs are listed in Supplementary Table 4 . Anti-CD11b (PerCP/Cy5.5), anti-F4/80 (APC), and anti-Ly6G (PE) were purchased from Biolegend (CA, USA). Lipofectamine™ 3000, and Lipofectamine™ MessengerMAX™ reagent were purchased from Invitrogen (CA, USA). Ultrapure LPS and glyburide were obtained from Invivogen (CA, USA). MSU, nigericin, ATP, and silica were purchased from Sigma (MO, USA).
Preparation of CLAN library and CLAN mCas9/gRNA . CLAN Cy5-siRNA were prepared by the double emulsion method according to our previous reports 61, 62 . In brief, Cy5-siRNA (200 μg in 25 μl RNase free water) was emulsified in 500 μl of chloroform containing different amounts of BHEM-Chol, PEG 5K -b-PLGA 11K and PLGA 11K for 1 min at 80 W over an ice bath using Vibra-Cell VCX130 from Sonics & Materials, Inc. (Newtown, USA). Subsequently, 5 ml of RNase-free water was added, and the mixture was further emulsified before removing chloroform by a rotary evaporator. To prepare a CLAN library of different nano-properties, the weight of BHEM-Chol was adjusted to 1, 1.5, 2, and 3 mg, while the mass fraction of PEG 5K -b-PLGA 11K in the polymer was adjusted to 100, 91.3, 86.4, and 81.4% ( Supplementary Fig. 1 ). The accurate weight of PEG 5K -b-PLGA 11K in 500 μl of chloroform was 25, 21.9, 20.3, and 18.8 mg, while the weight of PLGA 11K was simultaneously changed to 0, 2.1, 3.2, and 4.3 mg ( Supplementary Fig. 1 ). Similar to CLAN Cy5-siRNA , CLAN mCas9/gRNA was also prepared by the double emulsion method by dissolving 125 μg of mCas9 and 75 μg of gRNA in 25 μl of RNase-free water, in which the molar ratio of mCas9/gRNA was 1/25.
Characterization of CLAN Cy5-siRNA and CLAN mCas9/gRNA . The diameter and zeta potential of CLAN Cy5-siRNA and CLAN mCas9/gRNA were characterized using the Malvern Zetasizer Nano ZS90 system (Worcestershire, UK) as described previously 61 . The mass fraction of PEG 5K -b-PLGA 11K incorporated in CLAN was detected by 1 H NMR spectroscopy. CLAN Cy5-siRNA and CLAN mCas9/gRNA were destructed by dimethylsulfoxide, and then Cy5-siRNA and mCas9/gRNA were displaced by 10 mg ml −1 heparin sodium at 25°C for 1 h, followed by extraction to measure the encapsulation efficiency. The encapsulation efficiency of Cy5-siRNA in CLAN Cy5-siRNA was measured by HPLC according to our previous report 61 . The encapsulation efficiency of mCas9 and gRNA in CLAN mCas9/gRNA was measured using the Quant-iT™ RiboGreen® RNA Reagent and Kit (Thermo Fisher Scientific, MA, USA) according to the manufacturer's protocol. The morphology of CLAN mCas9/gRNA was tested by JEOL-2010 microscopy (Tokyo, Japan) at an accelerating voltage of 200 kV. The colloidal stability of CLAN mCas9/gRNA was examined in PBS with 10% FBS at 37°C, and the diameter was characterized at various incubation times. The integrity of mCas9 and gRNA in CLAN mCas9/gRNA was confirmed by 2% RNA denaturing gel electrophoresis after extracting mCas9/ gRNA from CLAN mCas9/gRNA .
Mice. C57BL/6 mice were purchased from Beijing HFK Bioscience (Beijing, China) and were housed in the specific pathogen-free facility in University of Science and Technology of China. At the end of experiments, all mice were killed by CO 2 inhalation. All animal experiments were approved by the Ethics Committee of the University of Science and Technology of China.
Cell preparation. Primary BMDMs were derived from the tibia and femoral bone marrow cells as described previously and were cultured in DMEM supplemented with 10% FBS (ExCell Bio Inc., Shanghai, China) 8, 16 . Raw264.7-GFP cells were established by transfecting Raw264.7 cells (ATCC) with the CRISPR/Cas9 plasmid and GFP knockin donor plasmid to stably express GFP with β-actin. Monoclonal Raw264.7-GFP cells were amplified and maintained in DMEM supplemented with 10% FBS. Raw264.7 and Raw264.7-GFP cells were routinely tested for mycoplasma contamination.
FACS analysis of CLAN with higher macrophage uptake. CLAN Cy5-siRNA of different nano-properties was intravenously injected into C57BL/6 mice (6 weeks, n = 3 per group) at the Cy5-siRNA dose of 1 mg kg −1 (i.e., 20 μg per mouse). Next, macrophages of the peritoneal cavity or immunocytes of the liver, peripheral blood, spleen, and adipose tissue were harvested 24 h after injection. Peritoneal macrophages were isolated by washing the peritoneal cavity with 10 ml of cold PBS. Liver and adipose tissue were digested with 2 mg ml −1 collagenase I/II for 45 min at 37°C
, and then immunocytes were purified with 40% percoll (GE Healthcare, UK) according to the manufacturer's protocol. Spleen immunocytes were isolated by filtering the spleen through nylon-wool-glass beads to obtain a single-cell suspension. Subsequently, isolated macrophages or immunocytes were treated with red blood cell lysis buffer (Stemcell, Vancouver, Canada) and were stained with anti-CD11b and anti-F4/80 antibodies to label macrophages. The cellular uptake of CLAN Cy5-siRNA by macrophages was assessed by FACSVerse (BD, Bedford, USA). The percentage of Cy5-positive macrophages and the mean fluorescence intensity (MFI) of Cy5 in positive macrophages were analyzed with Flowjo 7.6.1. The relative uptake quantity of CLAN Cy5-siRNA was calculated by the following formula: Relative uptake quantity ¼ Percentage of Cy5 MFI of Cy5 ð Þ =100%.
Selecting CLAN for mCas9/gRNA delivery. To detect Cas9-EGFP mRNA expression or GFP knockout efficiency, BMDMs or Raw264.7-GFP cells were plated in 6-well plates (10 6 cells per well) and were incubated overnight. Next, the medium was replaced, and cells were transfected with CLAN mCas9-EGFP/gNC at the final concentration of 2.6 nM mCas9-EGFP or CLAN mCas9/gGFP at the final concentration of 2.6 nM mCas9. ARTICLE to mark nucleus. The localization of CLAN42 and Cas9 protein was visualized by Ti-E A1 confocal microscope (Nikon, Tokyo, Japan).
To analyze the integrity of CLAN42, FITC and Rhodamine were selected as the donor and acceptor molecules of FRET couple, respectively. The emission spectrum of CLAN FRET , CLAN FITC , and CLAN Rho were detected with RF-6000 fluorescence spectrophotometer (Shimadzu, Tokyo, Japan) with the excitation light of 488 nm. Subsequently, we incubated BMDMs with CLAN FRET for 6 h at the concentration of 2.6 nM mCas9. At different time points (0, 6, 12, and 24 h) after transfection, BMDMs were collected, and stained with Alexa Fluor 647-labeled EEA1 antibody to mark endosome and DAPI to mark nucleus. The fluorescence of FITC and Rhodamine were observed with confocal microscope (Ti-E A1, Nikon, Tokyo, Japan) using the excitation light of 488 nm.
BMDM transfection and stimulation. BMDMs were plated in 6-well plates (10 6 cells per well) and were incubated overnight. Next, the medium was replaced, and cells were transfected with CLAN mCas9/gNLRP3 or other formulations for 6 h. CLAN mCas9/gNLRP3 was transfected at the dose of 0.85, 1.7, and 2.6 nM mCas9. Lipo mCas9/gNLRP3 was transfected at the dose of 0.85 nM mCas9, while Lipo pCas9/ gNLRP3 was transfected at 0.23 nM of pX330/gNLRP3 plasmid-i.e., 1.25 μg ml −1 for both mRNA and plasmid. Free mCas9/gNLRP3 and CLAN mCas9/gNC were transfected at the dose of 2.6 nM mCas9 and was used as the negative control. To stimulate the activation of the NLRP3 inflammasome, 72 h after CLAN mCas9/gNLRP3 transfection, cells were primed with 500 ng ml −1 LPS for 3 h and then were stimulated with nigericin (10 μM) for 30 min or MSU (150 μg ml −1 ) for 4 h or ATP (2.5 mM) for 30 min or silica (500 μg ml −1 ) for 6 h. The supernatants and BMDMs were then collected for immunoblotting or ELISA or the ASC oligomerization assay. For glyburide, LPS-primed BMDMs were pretreated with glyburide (200 μM) for 30 min and then were stimulated with nigericin.
Immunoblot analysis. Cell lysates were prepared by lysing BMDMs and peritoneal macrophages in Laemmli sample buffer. The protein content of supernatants or serum was concentrated using StrataClean resin (Agilent, CA, USA). WAT proteins were extracted using the Total Protein Extraction Kit for Adipose Tissues (Invent, MN, USA). All protein samples were prepared according to the manufacturer's instructions, separated by 12% SDS-PAGE and transferred to PVDF membranes using a wet-transfer system. The membranes were blocked in TBST buffer containing 5% (wt/vol) BSA for 2 h at room temperature and then were incubated with primary antibody diluted in TBST buffer containing 1% (wt/vol) BSA overnight at 4°C. The membranes were further incubated with HRPconjugated secondary antibody diluted in TBST buffer containing 1% (wt/vol) BSA for 1 h at room temperature. Finally, the membranes were developed using SuperSignal Chemiluminescent Substrates (Thermo Fisher Scientific, MA USA). Uncropped scans of the most important blots were shown in Supplementary  Fig. 15-18 .
Primary antibodies: Anti-Cas9 (ab191468, 1:1000) and anti-NLRP1 (ab3683, 1:1000) antibodies were from Abcam (Shanghai, China). Anti-NLRP3 (AG-20B-0014, 1:1000) and anti-ASC (AL177, 1:1000) antibodies were from Adipogen (CA, USA). Anti-NLRC4 (06-1125, 1:1000) antibody was from EMD Millipore (MA, USA). Anti-AIM2 (sc-137967, 1:1000), anti-caspase-1 p10 (sc-514, 1:1000), and anti-β-actin antibodies were from Santa Cruz (CA, USA). Anti-IL1β (AF-401-NA, 1:1000) was from R&D (MN, USA). Secondary HRP-conjugated antibodies antimouse IgG, anti-rabbit IgG and anti-goat IgG (all 1:1000) were from EMD Millipore (MA, USA).
ASC oligomerization assay. BMDMs were washed in cold PBS, and 500 µl of cold buffer (20 mM HEPES-KOH, pH 7.5, 150 mM KCL, 1% NP-40, 0.1 mM PMSF, 1 mg ml −1 leupeptin, 11.5 mg ml −1 aprotinin, and 1 mM sodium orthovanadate) was added. Cells were dissolved on the shaker for 30 min at 4°C and then were centrifuged at 330 × g for 10 min at 4°C. The pellets were washed twice in 1 ml of cold PBS and were resuspended in 500 µl of cold PBS. Next, 2 mM disuccinimydyl suberate (Sigma, MO, USA) was added to the resuspended pellets, which were incubated for 30 min with rotation at room temperature. Samples were then centrifuged at 330 × g for 10 min at 4°C. The supernatants were removed, and the cross-linked pellets were resuspended in 30 µl of Laemmli sample buffer. Samples were boiled for 10 min at 99°C and were analyzed by immunoblotting.
T7E1 assay and Sanger sequencing. Genomic DNA of BMDMs or peritoneal macrophages was extracted using the AxyPrep multisource genomic DNA miniprep kit according to the manufacturer's instructions. The flanking region of the gNLRP3 targeting sequence and its potential off-targets was amplified by PCR (Ontarget and off-targets of gNLRP3, as well as primers for PCR amplification, are listed in Supplementary Table 5- 7) . Two hundred nanograms of purified PCR products was first diluted in 20 μl of NEBuffer 2 and was denatured at 95°C for 5 min. The denatured PCR products were then reannealed at 95-85°C (ramp rate: −2°C s −1 ) and at 85-25°C (ramp rate: −0.1°C s −1 ). After cooling down to 4°C, 1 μl of T7E1 (NEB, Beijing, China) was added and incubated at 37°C for 15 min. Finally, 1.5 μl of 0.25 M EDTA was added to stop the reaction. The fragmented PCR products were analyzed with 2% agarose gel electrophoresis, and the percent of nuclease-specific cleavage products (fraction cleaved) was determined by Image J. The gene knockout efficiency was calculated using the following formula: Indel frequency (%) = 100% 1 À ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi ffi 1 À fraction cleaved p À Á . The PCR products of the genomic region-flanking target sites of gNLRP3 were cloned into the T-clone vector for Sanger sequencing by General Biosystems (Anhui, China).
ELISA. Supernatants from cells or WAT culture, serum, and peritoneal lavage fluid were analyzed using IL-1β, IL-18, TNF-α, and MCP-1 ELISA kits according to the manufacturer's instructions. Mouse IL-1β/IL-1F2 ELISA kit (DY401) was from R&D (MN, USA). ELISA detection kits for mouse IL-18 (ELM-IL18), TNF-α (ELM-TNFa), and MCP-1 (ELM-MCP1) were from RayBiotech (GA, USA).
Mitigation of LPS-induced septic shock. C57BL/6 mice (6-8 weeks, n = 8 per group) were first injected with CLAN mCas9/gNLRP3 at the dose of 1, 2, or 4 mg kg −1 total RNA for three injections. Mice injected with PBS and Free mCas9/gNLRP3 (4 mg kg −1 ), CLAN mCas9/gNC (4 mg kg −1 ) were used as negative controls. Mice intraperitoneally injected with MCC950 (50 mg kg −1 ) were used as positive controls. Two days after the last CLAN mCas9/gNLRP3 injection, all mice were intraperitoneally injected with LPS (20 mg kg −1 ) to induce septic shock. Next, mice were further observed to construct a survival curve or were sacrificed at 4 h after LPS injection to collect serum and peritoneal macrophages. Serum was subjected to immunoblotting to detect IL-1β or caspase p10 or ELISA to measure the IL-1β, IL-18 and TNFα concentrations. Peritoneal macrophages were subjected to immunoblotting to detect the NLRP3 knockout efficiency.
Mitigation of MSU-induced peritonitis. C57BL/6 mice (6-8 weeks, n = 5 per group) were first injected with CLAN mCas9/gNLRP3 at the dose of 1 or 4 mg kg −1 total RNA for three injections. Mice injected with PBS, Free mCas9/gNLRP3 (4 mg kg −1 ), CLAN mCas9/gNC (4 mg kg −1 ) were used as controls. Two days after the last CLAN mCas9/gNLRP3 injection, all mice were intraperitoneally injected with MSU (40 mg kg −1 ) to induce peritonitis. The mice were then sacrificed at 6 h after MSU injection, and the peritoneal cavities were washed with 10 ml of cold PBS. Neutrophils in the peritoneal lavage fluid were labeled with anti-CD11b and anti-Ly6G antibodies and were analyzed by FACS to detect neutrophil recruitment. The concentration of IL-1β in peritoneal lavage fluid was measured by ELISA. Peritoneal macrophages were subjected to immunoblotting to detect the NLRP3 knockout efficiency.
